Cardiac Amyloidosis
AI accurately diagnosed cardiac amyloidosis on echocardiography
A new AI model accurately detected cardiac amyloidosis from echocardiograms with higher accuracy vs. other amyloidosis risk scores, according to research published in the European Heart Journal.
VIDEO: Concomitant tafamidis, acoramidis use does not alter any ATTRibute-CM endpoints
Results of prespecified analyses, presented at the American College of Cardiology Scientific Session, found that tafamidis use in conjunction with acoramidis use did not alter the primary efficacy endpoints of the ATTRibute-CM study.
Vutrisiran improves cardiac amyloidosis endpoints regardless of disease severity
CHICAGO — Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for a broad spectrum of patients with transthyretin amyloidosis with cardiomyopathy, subgroup analyses show.
CRISPR gene-editing therapy shows promise as cardiac amyloidosis treatment in early study
CHICAGO — A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin reduced transthyretin levels in patients with cardiac amyloidosis, researchers reported at the American Heart Association Scientific Sessions.
Artificial intelligence using ECG criteria could assist diagnosis of HFpEF
Individuals with undiagnosed HF with preserved ejection fraction represent an at-risk group whose diagnosis could be improved by artificial intelligence trained with electronic health record data, according to researchers in the U.K.
Carpal tunnel syndrome may be early predictor of heart failure risk
Adults with a diagnosis of carpal tunnel syndrome are 39% more likely to develop HF during 10 years of follow-up, especially amyloidosis, compared with those without a carpal tunnel syndrome diagnosis, researchers reported.
AI algorithm for detection of cardiac amyloidosis gains FDA breakthrough device status
Anumana announced it received FDA breakthrough device designation for its artificial intelligence-guided ECG algorithm for the early identification of cardiac amyloidosis.
AI-enhanced platform for detecting cardiac amyloidosis nets FDA breakthrough device status
Ultromics announced it has received FDA breakthrough device status for its artificial intelligence-enhanced platform for detecting cardiac amyloidosis on echocardiograms.
Heart transplant feasible option for end-stage cardiac amyloidosis
Heart transplant is a viable treatment option for adults at an advanced stage of cardiac amyloidosis, as overall survival after transplantation has continued to improve over 3 decades, data from a retrospective study show.
Top in cardiology: Surge in CVD deaths; cardiac amyloidosis guidance
CVD-related deaths increased from 874,613 in 2019 to 928,741 in 2020, according to a report from the American Heart Association.